BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
BeyondSpring (NASDAQ: BYSI) has announced a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation will focus on the 303 Study, an investigator-initiated study supported by Merck and BeyondSpring, examining the combination of Pembrolizumab, Plinabulin, and Docetaxel in second and third-line non-small cell lung cancer (NSCLC) patients who progressed on PD-1/PD-L1 inhibitors.
The presentation, titled "Phase 2 Study of Pembrolizumab plus Plinabulin and Docetaxel for Patients with Metastatic NSCLC," will be delivered on May 31, 2025, from 1:30 PM to 4:30 PM CDT at the McCormick Place Convention Center. The study focuses on efficacy and safety results related to immune re-sensitization in patients who progressed after first-line immune checkpoint inhibitor therapy.
BeyondSpring (NASDAQ: BYSI) ha annunciato una presentazione poster al Meeting Annuale 2025 della American Society of Clinical Oncology (ASCO) a Chicago. La presentazione riguarderà lo Studio 303, uno studio avviato da investigatori e supportato da Merck e BeyondSpring, che analizza la combinazione di Pembrolizumab, Plinabulin e Docetaxel in pazienti con carcinoma polmonare non a piccole cellule (NSCLC) in seconda e terza linea, che hanno mostrato progressione della malattia dopo trattamento con inibitori PD-1/PD-L1.
La presentazione, intitolata "Studio di Fase 2 di Pembrolizumab più Plinabulin e Docetaxel in pazienti con NSCLC metastatico", si terrà il 31 maggio 2025, dalle 13:30 alle 16:30 CDT presso il McCormick Place Convention Center. Lo studio si concentra sui risultati di efficacia e sicurezza relativi alla ri-sensibilizzazione immunitaria in pazienti che hanno avuto progressione dopo la terapia con inibitori del checkpoint immunitario di prima linea.
BeyondSpring (NASDAQ: BYSI) ha anunciado una presentación en formato póster en la Reunión Anual 2025 de la American Society of Clinical Oncology (ASCO) en Chicago. La presentación se centrará en el Estudio 303, un estudio iniciado por investigadores y apoyado por Merck y BeyondSpring, que evalúa la combinación de Pembrolizumab, Plinabulin y Docetaxel en pacientes con cáncer de pulmón no microcítico (NSCLC) en segunda y tercera línea que progresaron tras inhibidores de PD-1/PD-L1.
La presentación, titulada "Estudio de Fase 2 de Pembrolizumab más Plinabulin y Docetaxel para pacientes con NSCLC metastásico", se realizará el 31 de mayo de 2025, de 1:30 PM a 4:30 PM CDT en el McCormick Place Convention Center. El estudio se enfoca en los resultados de eficacia y seguridad relacionados con la re-sensibilización inmune en pacientes que progresaron después de la terapia con inhibidores de puntos de control inmunitarios de primera línea.
BeyondSpring (NASDAQ: BYSI)가 2025년 시카고에서 열리는 미국 임상종양학회(ASCO) 연례회의에서 포스터 발표를 진행할 예정입니다. 이번 발표는 머크와 BeyondSpring이 지원하는 연구자가 주도한 303 연구를 중심으로, PD-1/PD-L1 억제제 치료 후 진행된 2차 및 3차 비소세포폐암(NSCLC) 환자들을 대상으로 펨브롤리주맙, 플리나불린, 독세탁셀 병용 요법을 조사합니다.
"전이성 NSCLC 환자를 위한 펨브롤리주맙과 플리나불린 및 독세탁셀의 2상 연구"라는 제목의 발표는 2025년 5월 31일 오후 1시 30분부터 4시 30분까지 CDT 시간대에 맥코믹 플레이스 컨벤션 센터에서 진행됩니다. 본 연구는 1차 면역관문억제제 치료 후 진행된 환자들의 면역 재감작에 따른 효능 및 안전성 결과에 중점을 두고 있습니다.
BeyondSpring (NASDAQ : BYSI) a annoncé une présentation sous forme de poster lors de la réunion annuelle 2025 de la American Society of Clinical Oncology (ASCO) à Chicago. La présentation portera sur l'étude 303, une étude initiée par des chercheurs et soutenue par Merck et BeyondSpring, qui examine la combinaison de Pembrolizumab, Plinabulin et Docetaxel chez des patients atteints de cancer du poumon non à petites cellules (NSCLC) en deuxième et troisième ligne, ayant progressé sous inhibiteurs PD-1/PD-L1.
La présentation, intitulée "Étude de phase 2 de Pembrolizumab plus Plinabulin et Docetaxel chez des patients atteints de NSCLC métastatique", aura lieu le 31 mai 2025 de 13h30 à 16h30 CDT au McCormick Place Convention Center. L'étude porte sur les résultats d'efficacité et de sécurité liés à la re-sensibilisation immunitaire chez des patients ayant progressé après un traitement de première ligne par inhibiteurs de points de contrôle immunitaire.
BeyondSpring (NASDAQ: BYSI) hat eine Posterpräsentation auf der Jahrestagung 2025 der American Society of Clinical Oncology (ASCO) in Chicago angekündigt. Die Präsentation wird sich auf die Studie 303 konzentrieren, eine von Forschern initiierte Studie, die von Merck und BeyondSpring unterstützt wird und die Kombination von Pembrolizumab, Plinabulin und Docetaxel bei Patienten mit nicht-kleinzelligem Lungenkrebs (NSCLC) in der zweiten und dritten Therapielinie untersucht, die unter PD-1/PD-L1-Inhibitoren Fortschreiten zeigten.
Die Präsentation mit dem Titel "Phase-2-Studie von Pembrolizumab plus Plinabulin und Docetaxel bei Patienten mit metastasiertem NSCLC" findet am 31. Mai 2025 von 13:30 bis 16:30 Uhr CDT im McCormick Place Convention Center statt. Die Studie fokussiert sich auf Wirksamkeits- und Sicherheitsdaten zur Immun-Re-Sensibilisierung bei Patienten, die nach der Erstlinientherapie mit Immun-Checkpoint-Inhibitoren Fortschritte zeigten.
- None.
- None.
FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL.
Presentation details are as follows:
- Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (Pts) with Metastatic NSCLC after Progression on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization
- Presenter / Author : Yan Xu, Minjiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Wei Zhong, RuiLi Pan, Mengzhao Wang
- Presentation Time: Saturday, May 31, 2025, at 1:30PM to 4:30PM CDT
- Location: McCormick Place Convention Center
- Session / Track: Lung Cancer – Non-Small Cell Metastatic
- Abstract Number: 8560
- Poster Board Number: 40
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and a range of cancer indications. Plinabulin’s novel mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors to checkpoint inhibitors. Learn more at beyondspringpharma.com.
About 303 Study
303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as the principal investigator and with Merck. The sample size of the study is 47 patients and all have been enrolled. The primary endpoint is investigator-based ORR (RECIST 1.1). The secondary endpoints include PFS, OS, DoR, and safety. The regimen includes Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1, Docetaxel 75 mg/m2 IV Q3W on Day 1 and Plinabulin 30mg/m2 IV Q3W on Day 1 in a 21-day cycle. The study is funded by Merck’s Investigator Studies Program and BeyondSpring with provision of study drug and financial support. The registration number is NCT05599789 on clinicaltrials.gov.
Investor Contact:
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com
FAQ
What will BeyondSpring (BYSI) present at ASCO 2025?
When and where is BeyondSpring's ASCO 2025 presentation scheduled?
What is the focus of BeyondSpring's 303 Study in NSCLC patients?
Who are the collaborators in BeyondSpring's 303 Study?
